Newly appointed ScinoPharm Taiwan Ltd (台灣神隆) president Tony Su (蘇崇銘) yesterday said that he would oversee the company’s transition amid immense changes in global markets and supply chains.
“My first responsibility at the company would be to oversee continuation of organizational restructuring and cost management,” Su told an earnings conference.
He said that the global market for generic drugs has been reshuffled by rapid consolidation and the company faces increasing challenges as prices trend lower.
Apart from changing its chief financial and research and development officers, there has not been a major shift in the management team, although key executives would take on additional roles to better align them with the company’s objectives, Su said.
Su was previously with Uni-President Enterprises Corp (UPE, 統一企業), a major investor in ScinoPharm.
ScinoPharm, which makes active pharmaceutical ingredients (APIs), as well as providing contract manufacturing and research services, said that it would begin to see profit contribution from a newly approved generic oncology injection that was developed with US-based Sagent Pharmaceutical Inc.
ScinoPharm said that its generic version of anti-thrombotic drug Fondaparinux in March gained approval from the US Food and Drug Administration and is to begin sales in the US in two to three months time.
The anti-thrombotic drug is also expected to gain market approval from Indian authorities and commence sales there this year, the company said.
This year, ScinoPharm has gained regulatory approval in China to supply generic APIs for a treatment for benign prostatic hyperplasia and a generic oncology injectible for myeloid leukemia in the US.
The company has observed a significant shift in China’s API supply chain as Beijing tightens environmental requirements, ScinoPharm marketing and sales vice president Portia Lin (林靜雯) said.
China has been ordering noncompliant manufacturers to shut down, leading to disruptions in the supply and pricing of chemicals, Lin said.
The company has minimized the disruption by importing from other markets, Lin said, adding that China’s new plant inspection regimen and stricter drug license approvals should help push out low-quality API suppliers.
The company reported that net income in the second quarter dipped 3 percent quarterly to NT$131 million (US$4.27 million), although revenue rose 14 percent to NT$986 million on the back of strong sales of colorectal cancer products. Earnings per share (EPS) were NT$0.17.
In the April-to-June period, gross margin and operating margin were 43 percent and 16 percent respectively, up from 39 percent and 14 percent in the previous period.
Overall, net income in the first half rose 5 percent annually to NT$267 million, or EPS of NT$0.34, while sales gained 4 percent to reach NT$1.85 billion.
The New Taiwan dollar is on the verge of overtaking the yuan as Asia’s best carry-trade target given its lower risk of interest-rate and currency volatility. A strategy of borrowing the New Taiwan dollar to invest in higher-yielding alternatives has generated the second-highest return over the past month among Asian currencies behind the yuan, based on the Sharpe ratio that measures risk-adjusted relative returns. The New Taiwan dollar may soon replace its Chinese peer as the region’s favored carry trade tool, analysts say, citing Beijing’s efforts to support the yuan that can create wild swings in borrowing costs. In contrast,
Nvidia Corp’s demand for advanced packaging from Taiwan Semiconductor Manufacturing Co (TSMC, 台積電) remains strong though the kind of technology it needs is changing, Nvidia CEO Jensen Huang (黃仁勳) said yesterday, after he was asked whether the company was cutting orders. Nvidia’s most advanced artificial intelligence (AI) chip, Blackwell, consists of multiple chips glued together using a complex chip-on-wafer-on-substrate (CoWoS) advanced packaging technology offered by TSMC, Nvidia’s main contract chipmaker. “As we move into Blackwell, we will use largely CoWoS-L. Of course, we’re still manufacturing Hopper, and Hopper will use CowoS-S. We will also transition the CoWoS-S capacity to CoWos-L,” Huang said
VERTICAL INTEGRATION: The US fabless company’s acquisition of the data center manufacturer would not affect market competition, the Fair Trade Commission said The Fair Trade Commission has approved Advanced Micro Devices Inc’s (AMD) bid to fully acquire ZT International Group Inc for US$4.9 billion, saying it would not hamper market competition. As AMD is a fabless company that designs central processing units (CPUs) used in consumer electronics and servers, while ZT is a data center manufacturer, the vertical integration would not affect market competition, the commission said in a statement yesterday. ZT counts hyperscalers such as Microsoft Corp, Amazon.com Inc and Google among its major clients and plays a minor role in deciding the specifications of data centers, given the strong bargaining power of
INDUSTRY LEADER: INDUSTRY LEADER: Taiwan Semiconductor Manufacturing Co (TSMC, 台積電), a major chip supplier to Nvidia Corp and Apple Inc, yesterday said it aims to grow revenue by about 25 percent this year, driven by robust demand for artificial intelligence (AI) chips. That means TSMC would continue to outpace the foundry industry’s 10 percent annual growth this year based on the chipmaker’s estimate. The chipmaker expects revenue from AI-related chips to double this year, extending a three-fold increase last year. The growth would quicken over the next five years at a compound annual growth rate of 45 percent, fueled by strong demand for the high-performance computing
RSS